Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Maternal exposure to perfluorinated acids and fetal growth

Abstract

The widespread detection of perfluorinated acids (PFAs) in humans and known developmental toxicity in animals has raised concern about their potential effects on human reproductive health. Our objective was to determine whether increasing maternal exposure to PFAs is associated with adverse effects on fetal growth and length of gestation in women giving birth in Alberta, Canada. We examined the concentrations of perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS), and perfluorohexane sulfonate (PFHxS) in a cohort of 252 pregnant women who gave birth to live singletons. Each of the women had undergone an early second trimester prenatal screen, and her serum was analyzed for PFA concentrations. Data on infant and maternal variables were collected from the delivery record completed at birth. Adjusted changes in birth weight per natural log (ng/ml) of PFOA (median 1.5 ng/ml), PFHxS (median 0.97 ng/ml), and PFOS (median 7.8 ng/ml) were −37.4 g (95% confidence interval (CI): −86.0 to 11.2 g), 21.9 g (−23.4 to 67.2 g), and 31.3 g (−43.3 to 105.9 g), respectively. Mean birth weight z-score, standardized for gestational age and gender, length of gestation, and risk of preterm birth did not appear to be influenced by maternal PFA exposure. When PFA concentrations were divided into tertiles, similar patterns were observed. These results suggest that maternal PFA exposure has no substantial effect on fetal weight and length of gestation at the concentrations observed in this population.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  • Apelberg B.J., Witter F.R., Herstman J.B., Calafat A.M., Halden R.U., and Needham L.L., et al. Cord serum concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in relation to weight and size at birth. Environ Health Perspect 2007: 115: 1670–1676.

    Article  CAS  Google Scholar 

  • Case M.T., York R.G., and Christian M.S. Rat and rabbit oral developmental toxicology studies with two perfluorinated compounds. Int J Toxicol 2001: 20: 101–109.

    Article  CAS  Google Scholar 

  • Chan E., Sandhu M., Benskin J.P., Ralitsch M., Thibault N., and Birkholz D., et al. Endogenous high-performance liquid chromatography/tandem mass spectrometry interferences and the case of perfluorohexane sulfonate (PFHxS) in human serum; are we overestimating exposure? Rapid Commun Mass Spectrom 2009: 23: 1405–1410.

    Article  CAS  Google Scholar 

  • Dupont W.D., and Plummer W.D. PS power and sample size program available for free on the Internet. Controlled Clin Trials 1997: 18: 274.

    Article  Google Scholar 

  • Era S., Harada K.H., Toyoshima M., Inoue K., Minata M., and Saito N., et al. Cleft palate caused by perfluorooctane sulfonate is caused mainly by extrinsic factors. Toxicology 2009: 256: 42–47.

    Article  CAS  Google Scholar 

  • Fei C., McLaughlin J.K., Tarone R.E., and Olsen J. Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort. Environ Health Perspect 2007: 115: 1677–1682.

    Article  CAS  Google Scholar 

  • Frisbee S.J., Brooks A.P., Maher A., Flensborg P., Arnold S., and Fletcher T., et al. The C8 Health Project: design, methods, and participants. Environ Health Perspect 2009 doi: 10.1289/ehp.0800379.

    Article  CAS  Google Scholar 

  • Gabos S., Zemanek M., Cheperdak L., Kinniburgh D., Lee B., and Hrudey S., et al. Chemical biomonitoring in serum of pregnant women in Alberta (2005). A final report submitted to Alberta Health and Wellness May 2008 http://www.health.alberta.ca/documents/Chemical-Biomonitoring-2008.pdf., 2008.

  • Grice M.M., Alexander B.H., Hoffbeck R., and Kampa D.M. Self-reported medical conditions in perfluorooctanesulfonyl fluoride manufacturing workers. J Occup Environ Med 2007: 49: 722–729.

    Article  CAS  Google Scholar 

  • Hansen K.J., Clemen L.A., Ellefson M.E., and Johnson H.O. Compound-specific, quantitative characterization of organic fluorochemicals in biological matrices. Environ Sci Technol 2001: 35: 766–770.

    Article  CAS  Google Scholar 

  • Houde M., Martin J.W., Letcher R.J., Solomon K.R., and Muir D.C.G. Biological monitoring of perfluoroalkyl substances: a review. Environ Sci Technol 2006: 40: 3463–3473.

    Article  CAS  Google Scholar 

  • Inoue K., Okada F., Ito R., Kato S., Sasaki S., and Nakajima S., et al. Perfluorooctane sulfonate (PFOS) and related perfluorinated compounds in human maternal and cord blood samples: assessment of PFOS exposure in a susceptible population during pregnancy. Environ Health Perspect 2004: 112: 1204–1207.

    Article  CAS  Google Scholar 

  • Kennedy G.L., Butenhoff J.L., Olsen G.W., O’Connor J.C., Seacat A.M., and Perkins R.G., et al. The toxicology of perfluorooctanoate. Crit Rev Toxicol 2004: 34: 351–384.

    Article  CAS  Google Scholar 

  • Kramer M.S., Platt R.W., Wen S.W., Joseph K.S., Allen A., and Abrahamowicz M., et al. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics 2001: 108: E35.

    Article  CAS  Google Scholar 

  • Lau C., Thibodeaux J.R., Hanson R.G., Rogers J.M., Grey B.E., and Stanton M.E., et al. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. II: postnatal evaluation. Toxicol Sci 2003: 74: 382–392.

    Article  CAS  Google Scholar 

  • Midasch O., Drexler H., Hart N., Beckmann M.W., and Angerer J. Transplacental exposure of neonates to perfluorooctanesulfonate and perfluorooctanoate: a pilot study. Int Arch Occup Environ Health 2007: 80: 643–648.

    Article  CAS  Google Scholar 

  • Monroy R., Morrison K., Teo K., Atkinson S., Kubwabo C., and Stewart B., et al. Serum levels of perfluoroalkyl compounds in human maternal and umbilical cord blood samples. Environ Res 2008: 108: 56–62.

    Article  CAS  Google Scholar 

  • Nolan L.A., Nolan J.M., Shofer F.S., Rodway N.V., and Emmett E.A. The relationship between birth weight, gestational age and perfluorooctanoic acid (PFOA)-contaminated public drinking water. Reprod Toxicol 2009: 27: 231–238.

    Article  CAS  Google Scholar 

  • Olsen G.W., Burris J.M., Ehresman D.J., Froehlich J.W., Seacat A.M., and Butenhoff J.L., et al. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexane sulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 2007: 115: 1298–1305.

    Article  CAS  Google Scholar 

  • Olsen G.W., Mair D.C., Church T.R., Ellefson M.E., Reagen W.K., and Boyd T.M., et al. Decline in perfluorooctanesulfonate and other polyfluoroalkyl chemicals in American Red Cross adult blood donors, 2000–2006. Environ Sci Technol 2008: 42: 4989–4995.

    Article  CAS  Google Scholar 

  • Olsen G.W., Butenhoff J.L., and Zobel L.R. Perfluoroalkyl chemicals and human fetal development: an epidemiologic review with clinical and toxicological perspectives. Reprod Toxicol 2009: 27: 212–230.

    Article  CAS  Google Scholar 

  • Savitz D.A. Biomarkers of perfluorinated chemicals and birth weight. Environ Health Perspect 2007: 115: A528–A529.

    Article  Google Scholar 

  • Thibodeaux J.R., Hanson R.G., Rogers J.M., Grey B.E., Barbee B.D., and Richards J.H., et al. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. I: maternal and prenatal evaluations. Toxicol Sci 2003: 74: 369–381.

    Article  CAS  Google Scholar 

  • Tough S., Tofflemire K., and Jack M. Reproduction in Alberta: a look at the preconception, prenatal and postnatal periods, 2006. Prepared for the Alberta Centre for Child, Family and Community Research. http://www.research4children.com/public/data/documents/ReproductioninAlberta20060620pdf.pdf (updated March 2007, viewed 13 October, 2009).

  • Washino N., Saijo Y., Sasaki S., Kato S., Ban S., and Konishi K., et al. Correlations between prenatal exposure to perfluorinated chemicals and reduced fetal growth. Environ Health Perspect 2009: 117: 660–667.

    Article  CAS  Google Scholar 

  • Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004: 159: 702–706.

    Article  Google Scholar 

Download references

Acknowledgements

Igor Burstyn received salary support as a Population Health Investigator from the Alberta Heritage Foundation for Medical Research. Jonathan Martin received funding from NSERC Discovery, Alberta Health and Wellness, and the University Hospital Foundation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Igor Burstyn.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Appendix

Appendix

Table A1

Table a1 Distribution of risk factors for fetal growth restriction and neonatal morbidity, according to maternal perfluorinated acid (PFA) concentrations (ng/mL)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hamm, M., Cherry, N., Chan, E. et al. Maternal exposure to perfluorinated acids and fetal growth. J Expo Sci Environ Epidemiol 20, 589–597 (2010). https://doi.org/10.1038/jes.2009.57

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jes.2009.57

Keywords

This article is cited by

Search

Quick links